Clostridium difficile is a major nosocomial pathogen responsible for pseudo
membranous colitis and many cases of antibiotic-associated diarrhea. Becaus
e of potential relapse of disease with current antimicrobial therapy protoc
ols, there is a need for additional and/or alternative antimicrobial agents
for the treatment of disease caused by C. difficile. We have synthesized a
systematic series of 14 structurally simple bismuth compounds and assessed
their biological activities against C, difficile and four other gastrointe
stinal species, including Helicobacter pylori, Were, we report on Me activi
ties of six compounds that exhibit antibacterial activities against C. diff
icile, and some of the compounds have MICs of less than 1 mu g/ml. Also tes
ted, for comparison, were the activities of bismuth subcitrate and ranitidi
ne bismuth citrate obtained from commercial sources. C. difficile and H. py
lori were more sensitive both to the synthetic bismuth compounds and to the
commercial products than were Escherichia coli, Pseudomonas aeruginosa, an
d Protcus mirabilis, and the last three species were markedly resistant to
the commercial bismuth salts. Testing with human foreskin fibroblast cells
revealed that some of the Synthetic compounds were more cytotoxic than othe
rs. Killing curves for C. difficile treated with the more active compounds
revealed rapid death, and electron microscopy showed that the bismuth of th
ese compounds was rapidly incorporated bye, difficile, Energy dispersive sp
ectroscopy X-ray microanalysis of C, difficile cells containing electron-de
nse material confirmed the presence of internalized bismuth. Internalized b
ismuth was not observed in C, difficile treated with synthetic bismuth comp
ounds that lacked antimicrobial activity, which suggests that the uptake of
the metal is required for killing activity. The nature of the carrier woul
d seem to determine whether bismuth is transported into susceptible bacteri
a like C. difficile.